Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03750240 · ClinicalTrials.gov registry record · NA
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT03750240 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 2 participants.
The verdict
NCT03750240, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Neoadjuvant chemotherapy (NACT) is administered to treat invasive breast cancer before surgery. It offers the opportunity to evaluate tumor response to treatment in aggressive disease, and guide additional therapies for patients with inadequate response, if detected early. Investigators propose to develop a sodium breast MRI technique that will allow to assess the early metabolic response of breast cancer to NACT, occurring before late structural changes can be detected with standard MRI. This study will scan 12 patients using 1H/23Na MRI at 7 T and DCE MRI with triple-negative breast cancer undergoing AC-T therapy (2 months of Adriamycin + Cyclophosphamide, then 3 months of Taxol): at baseline (pre-NACT); after the first AC cycle (2 weeks); after AC treatment (2 months); after complete NACT (5 months, pre-surgery).
Interventions
- DIAGNOSTIC_TEST Sodium (Na) Magnetic Resonance Imaging (MRI)
- DIAGNOSTIC_TEST Dynamic Contrast- Enhanced (DCE) MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2021-06-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03750240
The ClinicalTrials.gov registry entry for NCT03750240 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium (Na) Magnetic Resonance Imaging (MRI) is the first listed.
NCT03750240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03750240 about?
NCT03750240 is a clinical study titled "Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy". Neoadjuvant chemotherapy (NACT) is administered to treat invasive breast cancer before surgery. It offers the opportunity to evaluate tumor response to treatment in aggressive disease, and guide additional therapies for patients with inadequate response, if detected early. Investigators propose to d...
What is the current status of trial NCT03750240?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2017-07-25. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT03750240?
The interventions under investigation include: Sodium (Na) Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST), Dynamic Contrast- Enhanced (DCE) MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03750240?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.